Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes - PubMed (original) (raw)
. 2007 Nov 1;110(9):3365-73.
doi: 10.1182/blood-2007-03-079673. Epub 2007 Jul 18.
Joop Gäken, Natalie A Twine, Wendy Ingram, Nigel Westwood, Nicholas C Lea, Janet Hayden, Nora Donaldson, Carlo Aul, Norbert Gattermann, Aristotle Giagounidis, Ulrich Germing, Alan F List, Ghulam J Mufti
Affiliations
- PMID: 17634407
- DOI: 10.1182/blood-2007-03-079673
Free article
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Azim Mohamedali et al. Blood. 2007.
Free article
Abstract
Low-risk myelodysplastic syndrome (MDS) with normal cytogenetics accounts for approximately 50% of MDS patients. There are no pathognomonic markers in these cases and the diagnosis rests on cytomorphologic abnormalities in bone marrow and/or peripheral blood. Affymetrix high-resolution single-nucleotide polymorphism (SNP) genotyping microarrays allow detection of cytogenetically cryptic genomic aberrations. We have studied 119 low-risk MDS patients (refractory anemia [RA] = 22; refractory cytopenia with multilineage dysplasia [RCMD] = 51; refractory anemia with ringed sideroblasts [RARS] = 12; refractory cytopenia with multilineage dysplasia with ringed sideroblasts [RCMD-RS] = 12; 5q- syndrome = 16; refractory anemia with excess blasts [RAEB] = 6) using SNP microarrays to seek chromosomal markers undetected by conventional cytogenetics. Loss of heterozygosity (LOH) detected by 50K arrays was verified using 250K and 500K arrays. We demonstrate the presence of uniparental disomy (UPD) in 46%, deletions in 10%, and amplifications in 8% of cases. Copy number (CN) changes were acquired, whereas UPDs were also detected in constitutional DNA. UPD on 4q was identified in 25% of RARS, 12% of RCMD with normal cytogenetics, 17% of RAEB, and 6% of 5q- syndrome cases. Univariate analysis showed deletions (P = .04) and International Prognostic Scoring System (IPSS; P < .001) scores correlated with overall survival; however, on multivariate analysis only IPSS scores retained prognostic significance (P < .001). We show, for the first time, that SNP microarray analysis in low-risk MDS patients reveals hitherto unrecognized UPD and CN changes that may allow stratification of these patients for early therapeutic interventions.
Similar articles
- Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW. Rosati S, et al. Leukemia. 1996 Jan;10(1):20-6. Leukemia. 1996. PMID: 8558932 - Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes.
Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Chaubey R, et al. Indian J Med Res. 2011 Oct;134(4):452-7. Indian J Med Res. 2011. PMID: 22089606 Free PMC article. - Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K. Svobodova K, et al. Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009. Epub 2016 Jan 24. Leuk Res. 2016. PMID: 26851439 - [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A, Mattern D, Köhler H, Hezel J, Lübbert M. Schmitt-Graeff A, et al. Pathologe. 2000 Jan;21(1):1-15. doi: 10.1007/s002920050001. Pathologe. 2000. PMID: 10663664 Review. German. - Significance of genome-wide analysis of copy number alterations and UPD in myelodysplastic syndromes using combined CGH - SNP arrays.
Ahmad A, Iqbal MA. Ahmad A, et al. Curr Med Chem. 2012;19(22):3739-47. doi: 10.2174/092986712801661121. Curr Med Chem. 2012. PMID: 22680919 Review.
Cited by
- Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.
Zhang L, Deeb G, Deeb KK, Vale C, Peker Barclift D, Papadantonakis N. Zhang L, et al. Cancers (Basel). 2024 Apr 15;16(8):1503. doi: 10.3390/cancers16081503. Cancers (Basel). 2024. PMID: 38672585 Free PMC article. Review. - Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
Qin Y, Zhang H, Feng L, Wei H, Wu Y, Jiang C, Xu Z, Zhu H, Liu T. Qin Y, et al. Ann Med. 2022 Dec;54(1):2627-2636. doi: 10.1080/07853890.2022.2125173. Ann Med. 2022. PMID: 36148999 Free PMC article. - Simultaneous brain cell type and lineage determined by scRNA-seq reveals stereotyped cortical development.
Anderson DJ, Pauler FM, McKenna A, Shendure J, Hippenmeyer S, Horwitz MS. Anderson DJ, et al. Cell Syst. 2022 Jun 15;13(6):438-453.e5. doi: 10.1016/j.cels.2022.03.006. Epub 2022 Apr 21. Cell Syst. 2022. PMID: 35452605 Free PMC article. - Guiding the global evolution of cytogenetic testing for hematologic malignancies.
Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Akkari YMN, et al. Blood. 2022 Apr 14;139(15):2273-2284. doi: 10.1182/blood.2021014309. Blood. 2022. PMID: 35167654 Free PMC article. - Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes.
Xiao X, He X, Li Q, Zhang W, Zhu H, Yang W, Li Y, Geng L, Liu H, Li L, Wang H, Fu R, Zhao M, Chen Z, Shao Z. Xiao X, et al. Front Oncol. 2020 Jul 7;10:962. doi: 10.3389/fonc.2020.00962. eCollection 2020. Front Oncol. 2020. PMID: 32733790 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous